Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

abstract：:Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...

journal_title：International clinical psychopharmacology

authors： Feighner JP,Boyer WF,Meredith CH,Hendrickson GG

更新日期：1989-07-01 00:00:00

abstract：:Platelet serotonin type 2A receptor (5-HT2A) sensitivity changes have previously been documented in depression, although it is unclear if this represents a stable trait marker of the illness, or whether it represents an acute state marker of depression that would change with treatment. Electroconvulsive therapy (ECT) ...

journal_title：International clinical psychopharmacology

authors： Plein H,Berk M

更新日期：2000-03-01 00:00:00

abstract：:Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

journal_title：International clinical psychopharmacology

authors： Eriksson E

更新日期：1999-05-01 00:00:00

abstract：:The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

journal_title：International clinical psychopharmacology

authors： Minot R,Luthringer R,Macher JP

更新日期：1993-01-01 00:00:00

abstract：:Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

journal_title：International clinical psychopharmacology

authors： Linden M

更新日期：1999-06-01 00:00:00

abstract：:Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

journal_title：International clinical psychopharmacology

authors： Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

更新日期：2014-03-01 00:00:00

abstract：:Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...

journal_title：International clinical psychopharmacology

authors： Davidson JR,Malik ML,Sutherland SN

更新日期：1997-11-01 00:00:00

abstract：:We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between...

journal_title：International clinical psychopharmacology

authors： Pae CU,Wang SM,Han C,Bahk WM,Lee SJ,Patkar AA,Masand PS,Serretti A,Emsley R

更新日期：2017-09-01 00:00:00

abstract：:A group of 13 untreated schizophrenic patients was collected over two and a half years. They were prescribed a standard regime of oral haloperidol, and where possible were transferred to haloperidol decanoate depot injections when their clinical condition stabilised. The progress of their symptoms was monitored weekly...

journal_title：International clinical psychopharmacology

authors： Leff JP,Tress KH

更新日期：1986-07-01 00:00:00

abstract：:Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

更新日期：2014-01-01 00:00:00

abstract：:It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...

journal_title：International clinical psychopharmacology

authors： Parker G

更新日期：2002-03-01 00:00:00

abstract：:Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

journal_title：International clinical psychopharmacology

authors： Fairweather DB,Kerr JS,Hindmarch I

更新日期：1993-04-01 00:00:00

abstract：:Hematological indices were measured in 8 patients with bipolar disorder during carbamazepine and carbamazepine-lithium combination treatment. Carbamazepine treatment was associated with limited reductions in white blood cell indices. Combined lithium-carbamazepine treatment reversed the reductions in total white cell ...

journal_title：International clinical psychopharmacology

authors： Joffe RT

更新日期：1988-01-01 00:00:00

abstract：:Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...

journal_title：International clinical psychopharmacology

authors： Hawley CJ,Roberts AG,Baldwin DS

更新日期：1994-04-01 00:00:00

abstract：:Methylamphetamine given intravenously as a single 15 mg dose led to a pronounced elevation of mood in 7 out of 21 depressed patients compared to a control injection of sterile water administered on another occasion in random order under double-blind conditions. All 7 responders experienced an increase of VAS self-rati...

journal_title：International clinical psychopharmacology

authors： Cookson J,Silverstone T

更新日期：1986-04-01 00:00:00

abstract：:A rational approach to the use of antidepressants in the elderly must consider the evidence as to whether such treatment is efficacious (in controlled trials) and effective in clinical practice. Effective treatment of depression depends on its detection, and the subsequent initiation and continuation of adequate treat...

journal_title：International clinical psychopharmacology

authors： Katona C

更新日期：1995-03-01 00:00:00

abstract：:Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

journal_title：International clinical psychopharmacology

authors： Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

更新日期：1999-01-01 00:00:00

abstract：:Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

journal_title：International clinical psychopharmacology

authors： Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

更新日期：2006-11-01 00:00:00

abstract：:Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of...

journal_title：International clinical psychopharmacology

authors： Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

更新日期：2014-09-01 00:00:00

abstract：:C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

journal_title：International clinical psychopharmacology

authors： Kim SH,Reaven G,Lindley S

更新日期：2011-01-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...

journal_title：International clinical psychopharmacology

authors： Agosti V,Stewart JW

更新日期：2007-09-01 00:00:00

abstract：:There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...

journal_title：International clinical psychopharmacology

authors： Newall H,Myles N,Ward PB,Samaras K,Shiers D,Curtis J

更新日期：2012-03-01 00:00:00

abstract：:Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

journal_title：International clinical psychopharmacology

authors： Varia I,Rauscher F

更新日期：2002-05-01 00:00:00

abstract：:Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

journal_title：International clinical psychopharmacology

authors： Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

更新日期：1996-06-01 00:00:00

abstract：:This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

journal_title：International clinical psychopharmacology

authors： Pae CU,Marks DM,Han C,Masand PS,Patkar AA

更新日期：2009-01-01 00:00:00

abstract：:A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. ...

journal_title：International clinical psychopharmacology

authors： Freeman H

更新日期：1997-07-01 00:00:00

abstract：:Severe orthostatic and cardiorespiratory dysregulation may occur during institution of clozapine therapy both during concomitant benzodiazepine medication and on reinstitution of clozapine after a washout period. Extensive medical and neurological workup before and after the trials can nevertheless be normal. The abse...

journal_title：International clinical psychopharmacology

authors： Bredbacka PE,Paukkala E,Kinnunen E,Koponen H

更新日期：1993-10-01 00:00:00

abstract：:In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

journal_title：International clinical psychopharmacology

authors： Lecrubier Y,Weiller E

更新日期：1997-10-01 00:00:00

abstract：:Since the discovery that clomipramine was effective in the treatment of obsessive-compulsive disorder (OCD), trials of several different medications for OCD have been published. The question of which agent, if any, is the medication of choice in OCD is of real clinical concern. Published clinical trials were collected...

journal_title：International clinical psychopharmacology

authors： Stein DJ,Spadaccini E,Hollander E

更新日期：1995-03-01 00:00:00